EP2407536 - ADP-ribosyl transferase fusion variant proteins [Right-click to bookmark this link] | Status | No opposition filed within time limit Status updated on 05.09.2014 Database last updated on 31.08.2024 | Most recent event Tooltip | 13.03.2020 | Change - lapse in a contracting state State(s) deleted from list of lapses: TR | published on 15.04.2020 [2020/16] | Applicant(s) | For all designated states Bioaxone Biosciences Inc. 1313 s. Andrew Avenue Fort Lauderdale, FL 33316 / US | [2012/26] |
Former [2012/03] | For all designated states Bioaxone Therapeutique Inc. Suite 200 7150 Frédérick-Banting Street Montréal, Québec H4S 2A1 / CA | Inventor(s) | 01 /
McKerracher, Lisa 302 2115 rue Saint-Urbain Montréal, Québec H2X 2N1 / CA | 02 /
Munzer, Jon Scott 15 Round Table Road Shrewsbury, MA 01545 / US | [2012/03] | Representative(s) | Patentanwälte Ruff, Wilhelm, Beier, Dauster & Partner mbB Postfach 10 40 36 70035 Stuttgart / DE | [N/P] |
Former [2012/03] | Patentanwälte Ruff, Wilhelm, Beier, Dauster & Partner Postfach 10 40 36 70035 Stuttgart / DE | Application number, filing date | 10195185.3 | 12.12.2007 | [2012/03] | Priority number, date | US20060643940 | 22.12.2006 Original published format: US 643940 | US20070808773 | 12.06.2007 Original published format: US 808773 | [2012/03] | Previously filed application, date | WO2007CA02265 | 12.12.2007 | [2012/03] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | EP2407536 | Date: | 18.01.2012 | Language: | EN | [2012/03] | Type: | A9 Corrected patent application | No.: | EP2407536 | Date: | 13.03.2013 | [2013/11] | Type: | B1 Patent specification | No.: | EP2407536 | Date: | 30.10.2013 | Language: | EN | [2013/44] | Search report(s) | (Supplementary) European search report - dispatched on: | EP | 29.11.2011 | Classification | IPC: | C12N9/10, A61K38/45, A61K47/42, A61K47/48, A61K9/19, A61P25/00, A61P35/00, A61P35/04, A61P9/00, C07K14/435, C07K19/00 | [2012/03] | CPC: |
C12N9/1077 (EP,US);
A61K47/60 (EP,US);
A61P21/00 (EP);
A61P21/02 (EP);
A61P21/04 (EP);
A61P25/00 (EP);
A61P25/14 (EP);
A61P25/16 (EP);
A61P25/28 (EP);
A61P27/02 (EP);
A61P27/06 (EP);
A61P3/00 (EP);
A61P31/18 (EP);
A61P33/14 (EP);
A61P35/00 (EP);
A61P35/04 (EP);
A61P37/00 (EP);
A61P39/02 (EP);
A61P9/00 (EP);
A61P9/10 (EP);
A61K38/00 (EP,US);
| Designated contracting states | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR [2012/03] | Title | German: | ADP-Ribosyltransferase-Fusionsproteinvarianten | [2012/03] | English: | ADP-ribosyl transferase fusion variant proteins | [2012/03] | French: | Protéines variantes de fusion d'ADP-ribosyl transférase | [2012/03] | Examination procedure | 18.07.2012 | Amendment by applicant (claims and/or description) | 18.07.2012 | Examination requested [2012/35] | 09.08.2012 | Despatch of a communication from the examining division (Time limit: M06) | 19.02.2013 | Reply to a communication from the examining division | 06.05.2013 | Communication of intention to grant the patent | 16.09.2013 | Fee for grant paid | 16.09.2013 | Fee for publishing/printing paid | Parent application(s) Tooltip | EP07855547.1 / EP2118275 | Divisional application(s) | The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 09.08.2012 | Opposition(s) | 31.07.2014 | No opposition filed within time limit [2014/41] | Fees paid | Renewal fee | 15.12.2010 | Renewal fee patent year 03 | 15.12.2010 | Renewal fee patent year 04 | 14.12.2011 | Renewal fee patent year 05 | 18.12.2012 | Renewal fee patent year 06 |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Lapses during opposition Tooltip | BE | 30.10.2013 | BG | 30.10.2013 | CY | 30.10.2013 | CZ | 30.10.2013 | EE | 30.10.2013 | LT | 30.10.2013 | LV | 30.10.2013 | MT | 30.10.2013 | PL | 30.10.2013 | RO | 30.10.2013 | SI | 30.10.2013 | SK | 30.10.2013 | GR | 31.01.2014 | IS | 28.02.2014 | PT | 28.02.2014 | [2020/16] |
Former [2020/15] | BE | 30.10.2013 | |
BG | 30.10.2013 | ||
CY | 30.10.2013 | ||
CZ | 30.10.2013 | ||
EE | 30.10.2013 | ||
LT | 30.10.2013 | ||
LV | 30.10.2013 | ||
MT | 30.10.2013 | ||
PL | 30.10.2013 | ||
RO | 30.10.2013 | ||
SI | 30.10.2013 | ||
SK | 30.10.2013 | ||
TR | 30.10.2013 | ||
GR | 31.01.2014 | ||
IS | 28.02.2014 | ||
PT | 28.02.2014 | ||
Former [2019/29] | BE | 30.10.2013 | |
BG | 30.10.2013 | ||
CY | 30.10.2013 | ||
CZ | 30.10.2013 | ||
EE | 30.10.2013 | ||
LT | 30.10.2013 | ||
LV | 30.10.2013 | ||
MT | 30.10.2013 | ||
PL | 30.10.2013 | ||
RO | 30.10.2013 | ||
SI | 30.10.2013 | ||
SK | 30.10.2013 | ||
GR | 31.01.2014 | ||
IS | 28.02.2014 | ||
PT | 28.02.2014 | ||
Former [2016/28] | BE | 30.10.2013 | |
BG | 30.10.2013 | ||
CY | 30.10.2013 | ||
CZ | 30.10.2013 | ||
EE | 30.10.2013 | ||
LT | 30.10.2013 | ||
LV | 30.10.2013 | ||
MT | 30.10.2013 | ||
PL | 30.10.2013 | ||
RO | 30.10.2013 | ||
SI | 30.10.2013 | ||
SK | 30.10.2013 | ||
TR | 30.10.2013 | ||
GR | 31.01.2014 | ||
IS | 28.02.2014 | ||
PT | 28.02.2014 | ||
Former [2015/41] | BE | 30.10.2013 | |
BG | 30.10.2013 | ||
CY | 30.10.2013 | ||
CZ | 30.10.2013 | ||
EE | 30.10.2013 | ||
GR | 30.10.2013 | ||
LT | 30.10.2013 | ||
LV | 30.10.2013 | ||
MT | 30.10.2013 | ||
PL | 30.10.2013 | ||
RO | 30.10.2013 | ||
SI | 30.10.2013 | ||
SK | 30.10.2013 | ||
TR | 30.10.2013 | ||
IS | 28.02.2014 | ||
PT | 28.02.2014 | ||
Former [2015/38] | BE | 30.10.2013 | |
BG | 30.10.2013 | ||
CY | 30.10.2013 | ||
CZ | 30.10.2013 | ||
EE | 30.10.2013 | ||
GR | 30.10.2013 | ||
LT | 30.10.2013 | ||
LV | 30.10.2013 | ||
PL | 30.10.2013 | ||
RO | 30.10.2013 | ||
SI | 30.10.2013 | ||
SK | 30.10.2013 | ||
TR | 30.10.2013 | ||
IS | 28.02.2014 | ||
PT | 28.02.2014 | ||
Former [2015/35] | BE | 30.10.2013 | |
BG | 30.10.2013 | ||
CY | 30.10.2013 | ||
CZ | 30.10.2013 | ||
EE | 30.10.2013 | ||
LT | 30.10.2013 | ||
LV | 30.10.2013 | ||
PL | 30.10.2013 | ||
RO | 30.10.2013 | ||
SI | 30.10.2013 | ||
SK | 30.10.2013 | ||
TR | 30.10.2013 | ||
IS | 28.02.2014 | ||
PT | 28.02.2014 | ||
Former [2015/32] | BE | 30.10.2013 | |
CY | 30.10.2013 | ||
CZ | 30.10.2013 | ||
EE | 30.10.2013 | ||
LT | 30.10.2013 | ||
LV | 30.10.2013 | ||
PL | 30.10.2013 | ||
RO | 30.10.2013 | ||
SI | 30.10.2013 | ||
SK | 30.10.2013 | ||
TR | 30.10.2013 | ||
IS | 28.02.2014 | ||
PT | 28.02.2014 | ||
Former [2015/14] | BE | 30.10.2013 | |
CY | 30.10.2013 | ||
CZ | 30.10.2013 | ||
EE | 30.10.2013 | ||
LT | 30.10.2013 | ||
LV | 30.10.2013 | ||
PL | 30.10.2013 | ||
RO | 30.10.2013 | ||
SI | 30.10.2013 | ||
SK | 30.10.2013 | ||
IS | 28.02.2014 | ||
PT | 28.02.2014 | ||
Former [2014/37] | BE | 30.10.2013 | |
CY | 30.10.2013 | ||
CZ | 30.10.2013 | ||
EE | 30.10.2013 | ||
LT | 30.10.2013 | ||
LV | 30.10.2013 | ||
PL | 30.10.2013 | ||
RO | 30.10.2013 | ||
SK | 30.10.2013 | ||
IS | 28.02.2014 | ||
PT | 28.02.2014 | ||
Former [2014/36] | BE | 30.10.2013 | |
CY | 30.10.2013 | ||
EE | 30.10.2013 | ||
LT | 30.10.2013 | ||
LV | 30.10.2013 | ||
IS | 28.02.2014 | ||
PT | 28.02.2014 | ||
Former [2014/28] | BE | 30.10.2013 | |
CY | 30.10.2013 | ||
LT | 30.10.2013 | ||
LV | 30.10.2013 | ||
IS | 28.02.2014 | ||
PT | 28.02.2014 | ||
Former [2014/26] | BE | 30.10.2013 | |
CY | 30.10.2013 | ||
LT | 30.10.2013 | ||
LV | 30.10.2013 | ||
IS | 28.02.2014 | ||
Former [2014/25] | BE | 30.10.2013 | |
LT | 30.10.2013 | ||
LV | 30.10.2013 | ||
IS | 28.02.2014 | ||
Former [2014/23] | BE | 30.10.2013 | |
LT | 30.10.2013 | ||
IS | 28.02.2014 | ||
Former [2014/20] | LT | 30.10.2013 | Documents cited: | Search | [X]WO02083179 (BIOAXONE THERAPEUTIQUE INC [CA]) [X] 1-17 * the whole document *; | [X]WO2005030248 (BIOAXONE THERAPEUTIQUE INC [CA], et al) [X] 1-17 * the whole document *; | [X] - "Clostridium botulinum C3APLT protein in a pET vector.", Geneseq, (20030324), Database accession no. AAE32059, URL: EBI, XP002663653 [X] 1-17 * the whole document * | by applicant | CA2304981 | CA2300878 | CA2325842 | US5707643 | US5443505 | US5632984 | US5770589 | US5767079 | US5273530 | US6397849 | US6299895 | US5399163 | US5383851 | US5312335 | US5064413 | US4941880 | US4790824 | US4596556 | US4487603 | US4486194 | US4447233 | US4447224 | US4439196 | US4475196 | US7141428 | USRE39298E | USRE39321E | US4427650 | US4427651 | US4414976 | US4640834 | US5290552 | US5607694 | US5714370 | US5750657 | US5773418 | US5962405 | US5962420 | US6117425 | US6162241 | US6262236 | US6780411 | US2005271646 | EP0804257 | USRE39299E | - CHEN ET AL., PNAS, (2002), vol. 99, pages 9031 - 9036 | - DILLON, FEIG, METHODS IN ENZYMOLOGY: SMALL GTPASES AND THEIR REGULATORS PART. B, (1995), vol. 256, pages 174 - 184 | - CLARK ET AL., NATURE, (2000), vol. 406, pages 532 - 535 | - UEHATA ET AL., NATURE, (1997), vol. 389, page 990 | - LEE ET AL., FASEB J., vol. 15, pages 1886 - 1884 | - WILDE ET AL., J. BIOL. CHEM., (2000), vol. 275, page 16478 | - LEHMANN ET AL., J. NEUROSCI., (1999), vol. 19, pages 7537 - 7547 | - RIDLEY, HALL, CELL, (1992), vol. 70, pages 389 - 399 | - BOQUET ET AL., METH. ENZYMOL., (1995), vol. 256, pages 297 - 306 | - BARTHE ET AL., INFECTION AND IMMUNITY, (1998), vol. 66, page 1364 | - QUIGLEY HA, "Glaucoma: Macrocosm to Microcosm The Friedenwald Lecture", INVEST. OPHTHALMOL. VIS. SCI., (2005), vol. 46, pages 2663 - 2670 | - LEE DA, HIGGINBOTHAM EJ, "Glaucoma and its treatment: a review", AM. J. HEALTH-SYST. PHARM., (2005), vol. 62, pages 691 - 600 | - ANDERSON DR, "Collaborative Normal Tension Glaucoma Study", CURR. OPIN. OPHTHALMOL., (2003), vol. 14, pages 86 - 90 | - VAN'T VEER ET AL., NATURE, (2002), vol. 415, pages 530 - 536 | - FISCHER ET AL., J. NEUROSCIENCE, (2004), vol. 24, pages 8726 - 2740 | - SMITH, WATERMAN, AD. APPL.MATH., (1981), vol. 2, pages 482 - 489 | - NEEDLEMAN, WUNSCH, J.MOL.BIOL., (1970), vol. 48, pages 443 - 453 | - JANKNECHT ET AL., PROC. NATL. ACAD. SCI., (1981), vol. 88, page 8972 | - WINTON ET AL., J BIOL CHEM, (2002), vol. 277, pages 32820 - 32829 | - LASKO, MCKERRACHER, METHODS ENZYMOL., (2006), vol. 406, pages 512 - 520 | - UNOKI, LAVAIL, INVEST OPTHALMOL VIS. SCI., (1994), vol. 35, page 907 | - MORRISON ET AL., EXP. EYE RES., (1997), vol. 64, pages 85 - 96 | - MORRISON ET AL., PROGRESS IN RETINAL AND EYE RESEARCH, (2005), pages 217 - 240 | - FAKTOROVICH ET AL., NATURE, (1990), vol. 347, page 83 | - LAVAIL ET AL., PNAS USA, (1992), vol. 89, page 11249 | - ERICKSON ET AL., J STRUCT. BIOL., (1992), vol. 108, page 148 | - CAFFE ET AL., CURR. EYE RES., (1993), vol. 12, page 719 | - BERTRAND ET AL., J NEUROSCI, (2005), vol. 25, pages 1113 - 1121 | - DERGHAM ET AL., J NEUROSCI, (2002), vol. 22, pages 6570 - 6577 |